Neurocrine Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-142.5M | $-141.1M | $-88.9M | $-60.5M | $-46.1M | $5.0M | $37.6M | $-8.0M |
| Depreciation & Amortization | $2.4M | $1.5M | $1.0M | $827.0K | $671.0K | $657.0K | $694.0K | $1.4M |
| Depreciation | $2.4M | $1.5M | $1.0M | $800.0K | $700.0K | $700.0K | $700.0K | $1.4M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $42.5M | $28.5M | $28.4M | $10.4M | $6.8M | $5.5M | $2.9M | $3.1M |
| Net Cash from Operating Activities | $-94.3M | $-106.2M | $-38.0M | $-47.1M | $-29.6M | $-35.3M | $-698.0K | $49.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.9M | $4.1M | $1.9M | $1.6M | $545.0K | $971.0K | $750.0K | $315.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-251.3M | $113.0M | — | — | $5.3M | $-34.8M | $-3.5M | $-54.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $516.6M | $2.4M | — | — | $5.3M | $83.7M | $286.0K | $21.5M |
| Net Change in Cash | $171.4M | $9.1M | $43.2M | $-13.8M | $-19.0M | $13.6M | $-3.9M | $16.7M |
| Free Cash Flow | $-101.3M | $-110.3M | $-39.9M | $-48.8M | $-30.2M | $-36.3M | $-1.4M | $49.6M |